The division provides evidence-based, multidisciplinary, family-centered clinical care; is a national leader in quality improvement for cystic fibrosis and asthma; performs groundbreaking clinical trials in cystic fibrosis; provides exceptional education for pediatric pulmonology fellows and other healthcare professionals; and advocates for the health and well-being of all children with respiratory disease and sleep disorders.
Our multidisciplinary team of physician-scientists conducts various types of research to better understand respiratory and sleep disorders, develop ways to prevent such diseases, and improve treatment options for children. We participate in studies funded by the NIH, the Cystic Fibrosis Foundation, pharmaceutical companies and our own investigator-initiated studies. Research in our division has led to medical developments such as Kalydeco, the first drug available that targets the underlying cause of Cystic Fibrosis (CF) – a faulty gene and its protein product, CFTR. The FDA approved Kalydeco for people ages 6 and older with the G551D mutation of CF in January 2012.
Additionally, the division collaborates with other Lurie Children’s divisions and research programs, and other programs at the Feinberg School, and participates in national and international activities in quality improvement and patient safety to improve the care of children with respiratory disease and sleep disorders.